Biotechnology
AbbVie's Q2 FY2026 results showcased strong double-digit revenue growth driven by immunology products, while net income soared due to reduced non-cash charges, though Humira decline and regulatory risks remain.
Key risk: Humira Biosimilar Erosion
Humira net revenues fell 36% in Q2 and 38% in the first half, driven by direct biosimilar competition following loss of exclusivity. Continued erosion could significantly reduce a key revenue stream.
Other Biotechnology companies